title: 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
abstract: BACKGROUND
  Aim of this study was to determine the value of technetium-99m-hydrazinonicotinyl-Tyr3-octreotide (99mTc-ED-DA/HYNIC-TOC) in patients with somatostatin receptor (SSR) positive tumors of head and neck region.
  
  
  METHODS
  A total number of 16 patients were enrolled in this study. Planar whole body (WB) and single photon emission computed tomography (SPECT) images were acquired at 2 and 4 hours after the injection of approximately 670 MBq of 99mTc-EDDA/HYNIC-TOC. Additional single photon emission computed tomography/computed tomography (SPECT/CT) images of the head and neck region were acquired at 4h post tracer injection. Clinical and imaging follow up were taken as the reference standard.
  
  
  RESULTS
  There were 10 female and 6 male patients of age 57.7 ± 12.9 years (58.5; 32-78) years. 99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy (SRS) was TP in 13 patients, TN in two and FP in one. Follow up period for SRS was 31.1 ± 19.4 (29; 2-63) months. 99mTc-EDDA/HYNIC-TOC scintigraphy provided additional information in 50% of patients, with impact on patient management in the same percentage of patients. Distant metastases were found in nine out of 16 patients (56%). 99mTc-EDDA/HYNIC-TOC SRS had sensitivity of 100% (75.3-100%), specificity of 66.7% (9.4-99.2%), accuracy of 93.7%, positive predictive value of 92.9% (66.1-99.8%), and negative predictive value of 100% (15.8-100%).
  
  
  CONCLUSIONS
  Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC is very useful imaging method in the evalu-ation of patients with SSR positive tumors of head and neck region.
authors.affiliation: University Hospital Centre Zagreb, Croatia. mate.trogrlic@gmail.com.
authors.forename: Mate
authors.initials: M
authors.lastname: Trogrlic
authors.forename: Stanko
authors.initials: S
authors.lastname: Tezak
mesh_terms: D000328:Adult; D000368:Aged; D004492:Edetic Acid / Q000031:analogs & derivatives* / Q000737:chemistry; D005260:Female; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives* / Q000737:chemistry; D015609:Organotechnetium Compounds / Q000737:chemistry*; D017481:Receptors, Somatostatin / Q000378:metabolism*; D012680:Sensitivity and Specificity; D000072098:Single Photon Emission Computed Tomography Computed Tomography
chemical_list: D015609:Organotechnetium Compounds; D017481:Receptors, Somatostatin; C410263:technetium Tc 99m hydrazinonicotinyl-Tyr(3)-octreotide; C026058:EDDA; D004492:Edetic Acid; D015282:Octreotide
keywords: emission-computed; neuroendocrine tumors; receptors; single-photon; somatostatin; technetium 99m EDDA-HYNIC-Tyr (3)-octreotide; tomography